Building Better Biologics™

The mission that unites everyone at Zymeworks is to create biotherapeutics that allow patients to return home to their loved ones, disease free. We intend to advance the development of disruptive therapeutic platforms and impactful biotherapeutics, especially in areas of unmet need. We believe we are well-positioned to deliver on our mission. 

Our Platforms
Our proprietary platforms: Azymetric™, ZymeLink™, and EFECT™ can be easily used in combination with each other and with existing approaches without compromising manufacturability. Our platforms enables the development next-generation biotherapeutics to result in superior patient outcomes.
Our Pipeline
Our extensive pipeline focuses on the development of bispecific antibodies and bispecific ADCs across a wide range of therapeutic indications. Our lead asset, ZW25 (bispecific antibody), is based on our Azymetric™ platform, while our second candidate, ZW49 (bispecific antibody-drug conjugate), is based on our Azymetric™ and ZymeLink™ platforms.
News
News

Read our most recent news

Our Partners
We are looking for strategic partners to help further advance our deep pipeline of therapeutic candidates and to expand the utility of our best-in-class Azymetric™, ZymeLink™, and EFECT™ platforms. We have multiple partnerships with 9 global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, Johnson & Johnson, LEO Pharma, BeiGene, and Iconic Therapeutics.

Building Better Biologics™

The mission that unites everyone at Zymeworks is to create biotherapeutics that allow patients to return home to their loved ones, disease free. We intend to advance the development of disruptive therapeutic platforms and impactful biotherapeutics, especially in areas of unmet need. We believe we are well-positioned to deliver on our mission. 

News
News

Read our most recent news

Our Platforms
Our proprietary platforms: Azymetric™, ZymeLink™, and EFECT™ can be easily used in combination with each other and with existing approaches without compromising manufacturability. Our platforms enables the development next-generation biotherapeutics to result in superior patient outcomes.
Our Pipeline
Our extensive pipeline focuses on the development of bispecific antibodies and bispecific ADCs across a wide range of therapeutic indications. Our lead asset, ZW25 (bispecific antibody), is based on our Azymetric™ platform, while our second candidate, ZW49 (bispecific antibody-drug conjugate), is based on our Azymetric™ and ZymeLink™ platforms.
Our Partners
We are looking for strategic partners to help further advance our deep pipeline of therapeutic candidates and to expand the utility of our best-in-class Azymetric™, ZymeLink™, and EFECT™ platforms. We have multiple partnerships with 9 global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, Johnson & Johnson, LEO Pharma, BeiGene, and Iconic Therapeutics.